Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.

Oncotarget - 31 May 2016

Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Inao Toko, Sueta Aiko, Fujiwara Saori, Omoto Yoko, Iwase Hirotaka

Abstract excerpt

BACKGROUND: The measurement of circulating cell-free DNA (cfDNA) may transform the management of breast cancer patients. We aimed to investigate the clinical significance of sequential measurements of ESR1 mutations in primary breast cancer (PBC) and metastatic breast cancer (MBC) patients. RESULTS: ESR1 mutations ratio in the PBC groups was used as the minimum cutoff for determining increases in cfDNA ESR1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Breast Neoplasms

Share to Circulating Tumor DNA

Share to Estrogen Receptor alpha

Share to ESR1 gene

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 27102299
DOI: 10.18632/oncotarget.8839
PMCID: PMC5078029

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.PMID 27102299Read ↗

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsSemantic proximity Read ↗

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Semantic proximity Read ↗

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.Semantic proximity Read ↗

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Semantic proximity Read ↗

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.Semantic proximity Read ↗

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancerSemantic proximity Read ↗

Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot StudySemantic proximity Read ↗

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.Semantic proximity Read ↗

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.Semantic proximity Read ↗

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.